Neri Piergiorgio, Mariotti Cesare, Mercanti Lucia, Salvolini Simone, Giovannini Alfonso
Neuroscience Department, Ophthalmology Section, Polytechnic University of Marche, Ancona, Italy.
Int Ophthalmol. 2008 Dec;28(6):425-7. doi: 10.1007/s10792-007-9152-8. Epub 2007 Oct 13.
To report a case of contralateral vitritis following intravitreal bevacizumab (Avastin, Roche Pharma).
A 54-year-old man was treated with intravitreal bevacizumab (IB) for a choroidal neovascularization secondary to anisometropic high myopia in the right eye that did not respond to photodynamic treatment. After the second injection, he showed a moderate vitritis in the fellow un-injected eye a few hours later.
The patient was treated with a sub-Tenon's injection of 40 mg triamcinolone (Kenacort, Squibb) and entirely recovered his vision. No further complications were observed.
Although IB has a satisfactory safety profile, the possibility of unusual complications associated with the drug or the procedure itself should always be considered.
